Merkel cell polyomavirus T-antigen (MCPyV T-antigen)

Merkel cell polyomavirus (MCPyV) T-antigen refers to the early proteins, primarily Large T (LT) and Small T (sT), encoded by the MCPyV genome (Source: NIH, PubMed). These proteins are essential for viral replication and are the primary drivers of oncogenesis in Merkel cell carcinoma (MCC), a rare but aggressive skin cancer (Source: Nature Reviews Cancer). In MCC, the viral genome is typically integrated into the host DNA, and the LT antigen is truncated, losing its helicase activity but retaining its ability to bind and inhibit the Retinoblastoma (Rb) tumor suppressor protein (Source: PubMed, UniProt). The sT antigen contributes to transformation by promoting protein synthesis and stabilizing the LT protein (Source: PubMed). Because these viral proteins are constitutively expressed in tumor cells but absent in healthy human tissue, they represent ideal targets for therapeutic intervention, including T-cell therapies and therapeutic vaccines (Source: ClinicalTrials.gov). Current clinical strategies focus on leveraging the immunogenicity of these antigens to stimulate a robust anti-tumor immune response, often in combination with immune checkpoint inhibitors (Source: Journal of Clinical Oncology). Additionally, the detection of T-antigen expression and circulating antibodies serves as a critical biomarker for diagnosis and monitoring of MCC (Source: NIH).

Other names

MCPyV Large T-antigenMCPyV Small T-antigenMCPyV LTMCPyV sTMerkel cell polyomavirus early proteinMCPyV T-Ag

Induction of T-cell mediated cytotoxicity against cells expressing viral oncoproteins and blockade of PD-1/PD-L1 inhibitory signaling to restore anti-tumor immunity.